Cardiff Oncology, Inc. (CRDF) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Cardiff Oncology reported revenue of $593,000, down 13.2% from $683,000 the year before. Net income was -$45.9M (a -7732.0% net margin), or -$0.69 per diluted share. Operating margin was -8256.3%. Operating activities generated -$37.9M of cash, leaving -$38.0M of free cash flow. At fiscal year end, Cardiff Oncology held $61.9M in total assets against $16.5M in total liabilities, including $17.5M of cash and equivalents.
Open the full interactive Cardiff Oncology financials → Quarterly statements, key ratios, valuation history and price charts.
Cardiff Oncology Key Stats
| Share Price | $1.01 |
|---|---|
| Market Cap | $69.1M |
| Revenue YoY Growth | -13.2% |
| 52-Week Range | $0.81 – $3.21 |
| Shares Outstanding | 68.4 million (basic, 2026 Q2) |
Cardiff Oncology Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $365,993 | $359,000 | $386,000 | $488,000 | $683,000 | $593,000 |
| Operating Income | -$19.1M | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| Pre-Tax Income | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Diluted EPS | -$1.08 | -$0.73 | -$0.89 | -$0.93 | -$0.95 | -$0.69 |
Cardiff Oncology Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $120,000 | $243,000 | $41,000 | $104,000 |
| Net Income | -$11.3M | -$7.2M | -$12.3M | -$9.2M |
| Diluted EPS | -$0.17 | -$0.11 | -$0.18 | -$0.14 |
Cardiff Oncology Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $131.0M | $11.9M | $16.3M | $21.7M | $51.5M | $17.5M |
| Current Assets | $133.4M | $146.1M | $111.3M | $77.4M | $95.1M | $60.1M |
| Total Assets | $134.7M | $149.5M | $116.2M | $81.6M | $97.2M | $61.9M |
| Current Liabilities | $6.1M | $6.6M | $7.8M | $10.4M | $13.4M | $16.4M |
| Total Liabilities | $6.6M | $9.1M | $9.8M | $11.9M | $14.2M | $16.5M |
| Shareholders' Equity | $128.2M | $140.4M | $106.3M | $69.7M | $82.9M | $45.4M |
Cardiff Oncology Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$16.3M | -$23.0M | -$33.8M | -$30.9M | -$37.7M | -$37.9M |
| Cash From Investing | -$211,880 | -$131.4M | $38.1M | $36.2M | $13.7M | $1.3M |
| Cash From Financing | $137.3M | $35.5M | $75,000 | $0 | $53.8M | $2.6M |
| Free Cash Flow | -$16.5M | -$23.2M | -$34.8M | -$31.5M | -$37.8M | -$38.0M |
Figures from Cardiff Oncology's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Cardiff Oncology financials page for every line item.
Cardiff Oncology Company Profile
| Ticker | CRDF |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001213037 |
Frequently Asked Questions
What was Cardiff Oncology's revenue in fiscal 2025?
Cardiff Oncology (CRDF) reported revenue of $593,000 for fiscal 2025.
What is Cardiff Oncology's annual revenue history?
Cardiff Oncology's annual revenue by fiscal year: 2020: $365,993; 2021: $359,000; 2022: $386,000; 2023: $488,000; 2024: $683,000; 2025: $593,000.
What was Cardiff Oncology's net income in fiscal 2025?
Cardiff Oncology reported net income of -$45.9M for fiscal 2025.
What was Cardiff Oncology's earnings per share (EPS) in fiscal 2025?
Cardiff Oncology's diluted EPS was -$0.69 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Cardiff Oncology generate in fiscal 2025?
Cardiff Oncology generated -$38.0M of free cash flow in fiscal 2025.
What was Cardiff Oncology's revenue last quarter?
In its most recent reported quarter (2026 Q2), Cardiff Oncology reported revenue of $104,000.
How many shares of Cardiff Oncology are outstanding?
Cardiff Oncology reported a weighted average of 68.4 million basic shares outstanding in 2026 Q2.
What is Cardiff Oncology's market cap?
Based on its latest closing price, Cardiff Oncology (CRDF) has a market capitalization of about $69.1M.
When does Cardiff Oncology's fiscal year end?
Cardiff Oncology's fiscal year end, as registered with the SEC, is December 31.
Where is Cardiff Oncology headquartered?
Cardiff Oncology lists its business address in San Diego, California in its SEC filings.
Cardiff Oncology Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →